Modified Citrus Pectin and prostate (PSA)

What 2 graded rows on modified citrus pectin agree on for prostate (PSA), and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Modified Citrus Pectin page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Modified Citrus Pectin page, with its PubMed record.

Supplement

Modified Citrus Pectin Choose another

2 rows · 69 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is an open-label trial of 59 people (2021) and found an improvement.

The rows run from 10 to 59 people, published from 2003 to 2021: 2 single studies.

2 improved

Grade DPSA doubling time after local prostate cancer therapy · Improved
Open-label trial · n 59 · 2021 · Men with non-metastatic, biochemically relapsed prostate cancer
4.8 g three times a day · 6 months
78% responded (stable or falling PSA in 58% or a longer PSA doubling time in 75%, with negative scans); no grade 3–4 toxicity.
Row on the Modified Citrus Pectin page · PubMed 34959847 (opens PubMed)
Grade DPSA doubling time after local prostate cancer therapy (pilot) · Improved
Open-label trial · n 10 · 2003 · Men with rising PSA after prostatectomy, radiation or cryosurgery (13 enrolled)
Dose not stated in the abstract · 12 months
PSA doubling time lengthened in 7 of 10 men compared with before MCP.
Row on the Modified Citrus Pectin page · PubMed 14663471 (opens PubMed)